P. Langmuir

发表

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

Joanna Leadbetter, Lisa Polin, Catherine Wheeler, 2004, Clinical Cancer Research.

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

J. Waterton, P. LoRusso, A. Ryan, 2004, Clinical Cancer Research.

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Chih-Hsin Yang, F. de Marinis, J. Wolf, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

R. Herbst, J. Heymach, A. Ryan, 2008 .

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Yan Sun, Li Zhang, John V Heymach, 2010, The Lancet. Oncology.

Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL).

J. Vansteenkiste, F. Blackhall, J. Raats, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST).

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

Paul D. Martin, S. Oliver, P. Langmuir, 2010, Clinical pharmacokinetics.

JAK inhibitors and COVID-19

P. Guglielmelli, P. Langmuir, S. Constantinescu, 2022, Journal for ImmunoTherapy of Cancer.

Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial

Meilan K. Han, J. Ficker, M. Levine, 2022, The Lancet Rheumatology.

Bone marrow abnormalities in the non-obese diabetic mouse.

A. Bothwell, M. Bridgett, I. N. Crispe, 1993, International immunology.

A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer.

M. Schlumberger, M. Morse, D. Headley, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance.

T. Strom, L. Turka, Yongsheng Li, 2002, The Journal of clinical investigation.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm

S. Yeleswaram, P. Langmuir, B. Knorr, 2020, Delaware journal of public health.

Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

Keunchil Park, R. Perng, J. S. Lee, 2010 .

A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

M. Arbushites, J. Dipersio, M. Perales, 2020, Blood advances.

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

E. Baudin, A. Ryan, M. Santoro, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to J.-F. Chatal et al

E. Baudin, A. Ryan, M. Santoro, 2012 .

Allograft Rejection in a New Allospecific CD4+ TCR Transgenic Mouse

R. Mitchell, E. Palmer, L. Turka, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Evaluation of the role of body-surface-area dose adjustment of ZD6126, a novel vascular-targeting agent

I. Melezínek, P. Langmuir, C. Wheeler, 2004 .

Vandetanib for the Treatment of Thyroid Cancer

A. Yver, P. Langmuir, 2012, Clinical pharmacology and therapeutics.

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

R. Herbst, A. Ryan, H. Mann, 2009, Clinical Cancer Research.

Acute myeloid leukaemia in children.

B. Lange, R. Aplenc, P. Langmuir, 2001, Best practice & research. Clinical haematology.

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.

F. Locatelli, Stephanie J. Lee, N. Hollaender, 2021, The New England journal of medicine.

PU.1 is required for myeloid-derived but not lymphoid-derived dendritic cells.

L. Spain, A. Guerriero, E. Scott, 2000, Blood.

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.

L. Seymour, K. Ding, F. Shepherd, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

T. Tammela, V. Kataja, N. James, 2014, The Lancet. Oncology.

Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question1

E. Palmer, L. Turka, A. Wells, 2001, The Journal of Immunology.

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

Keunchil Park, Yuh-Min Chen, R. Perng, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

Edward S. Kim, J. Lee, A. Ryan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.

T. Tammela, V. Kataja, H. Joensuu, 2014 .

862 Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials

K. Fizazi, C. Massard, P. Bono, 2014 .

Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

R. Herbst, L. Paz-Ares, M. Sebastian, 2007 .

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Francisco Cervantes, Jason Gotlib, Alessandro M. Vannucchi, 2017, Journal of Hematology & Oncology.

Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20

L. Seymour, K. Ding, F. Shepherd, 2007 .

A phase II study of pazopanib in children, adolescents, and young adults with refractory solid tumors.

H. Tada, P. Langmuir, B. Weigel, 2015 .

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

T. Burn, Yanlong Li, M. Covington, 2020, Clinical Immunology.

Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC).

S. Lippman, D. Raben, E. Cohen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Keunchil Park, Yuh-Min Chen, R. Perng, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

9004 Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

J. Vansteenkiste, F. Blackhall, J. Raats, 2009 .

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

Paul D. Martin, S. Oliver, P. Langmuir, 2010, Clinical pharmacokinetics.

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study

J. Sancho, M. Hutchings, P. Langmuir, 2023, Hematological oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

P. Langmuir, S. Korfee, S. Kennedy, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.